Clinical trial · Interventional
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD 001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in combination with carboplatin, paclitaxel and bevacizumab
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RAD001 | Drug | Everolimus | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Step 1 Arm 1
- description
- 5mg/day RAD001 + Carboplatin + Paclitaxel
- interventionNames
- Drug: RAD001
- type
- EXPERIMENTAL
- label
- Step 1, Arm 2
- description
- 30mg/week RAD001 + Carboplatin + Paclitaxel
- interventionNames
- Drug: RAD001
- type
- EXPERIMENTAL
- label
- Step 2, Arm 1
- description
- 5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 23 Years
- Maximum age
- 76 Years
Show eligibility criteria text
Inclusion criteria: * Age over 18 years * Advanced Non Small Cell Lung Cancer (Stage IIIB/IV) * Ability to perform normal daily functions Exclusion criteria: * Chronic steroid treatment * Prior treatment with chemotherapy for advanced lung cancer * Prior treatment with mTOR inhibitors * Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions * Known sensitivity to platinum compounds, taxanes or bevacizumab * Other cancers within the past 5 years * Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available